Cu-7
(Copper)Phase 2Small molecule
Cu-7 is one of 54 small molecule programs targeting Glioblastoma. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
53
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
14
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
160 competitors in Glioblastoma
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Antabuse
TevaPhase 3
Feraheme
AAzurity Pharmaceuticals
Phase 3
Zejula
GGlaxo Dba Glaxosmithkline
Phase 3
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer1 trial
Prostate Cancer1 trial
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
Terminated·—·Phase 1·NCT02963051·9 enrolled
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
CU-7
NDA NDA017408
Jan 1, 1982
TATUM-T
NDA NDA018205
Nov 15, 1984
PARAGARD T 380A
NDA NDA018680
Feb 24, 2025
MIUDELLA
NDA NDA218201
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Copper. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Cu-7. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCoopersurgical